ChromaCode announced that the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) of ChromaCode’s real time PCR Assay to detect SARS-CoV-2, according to a press release from the company.
The company’s HDPCR SARS-CoV-2 Real-Time PCR Assay is intended to detect SARS-CoV-2 from nasopharyngeal swab specimens from patients suspected by their healthcare provider of having COVID-19. Later this year, ChromaCode, based in Carlsbad, CA, also said it plans to launch an assay that combines multiple respiratory viruses into a single test.
ChromaCode’s platform is built on the use of data science technology — including proprietary signal processing techniques — and cloud-computing algorithms to boost the performance of commonly used molecular diagnostics instruments and reagents.
